A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center.

Ruohao Xu, Xiaomei Chen, Chengxin Deng, Ping Wu, Minming Li, Suxia Geng, Peilong Lai, Zesheng Lu, Jianyu Weng, Xin DuPubMed 2019

Abstract

The aim of the present study was to conduct a retrospective analysis of efficacy and safety profiles of azacitidine (AZA) <i>versus.</i> decitabine (DAC) in Chinese patients with intermediate or higher-risk MDS, which was based on two clinical trials in a single center. A total of 40 included MDS patients diagnosed with refractory anemia with excess blast (RAEB) were from two independent clinic trials. Patients in each trial received either AZA (n = 19) or DAC (n = 21) respectively, and the effectiveness as well as the safety profile of the two drugs were compared. Patients treated with AZA showed a comparative efficacy to DAC group with regard to the overall response rate (73.7% <i>versus.</i> 76.2%, <i>P</i> = 0.86), overall survival (median: 19.3 <i>versus.</i> 20.8 months, <i>P</i> = 0.56), progression-free survival (median: 12.3 <i>versus.</i> 9.3 months, <i>P</i> = 0.43) and leukemia-free survival (median: 22.8 <i>versus.</i> 26.6 months, <i>P</i> = 0.62). Patients treated with DAC showed slightly higher incidence of severe hematological adverse events during the whole treatment. Comparing hematological AEs in each observation interval, a trend of higher percentage of neutropenia, leukopenia and anemia as well as treatment delays were seen during the first 6 cycles in the DAC group.
BibTeX
@inproceedings{xu2019retrospective,
  author = {Ruohao Xu and Xiaomei Chen and Chengxin Deng and Ping Wu and Minming Li and Suxia Geng and Peilong Lai and Zesheng Lu and Jianyu Weng and Xin Du},
  title = {{A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center.}},
  booktitle = {PubMed},
  year = {2019},
}

Loading related content...

Figure